Colchicine linked with risk reduction for myocardial infarction in gout patients: systematic review and meta-analysis.

Abstract

INTRODUCTION:

This meta-analysis aimed to identify the effect of colchicine on myocardial infarction (MI) in patients with gout.

METHODS:

In February 2021, a systematic computer-based search was conducted in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Data on patients with gout that compared colchicine versus others (no use of colchicine) were retrieved. The endpoints were the incidence rate for MI. After testing for heterogeneity between studies, data were aggregated for fixed-effects models when necessary.

RESULTS:

Three clinical studies with 3012 patients (colchicine group = 1523, control group = 1489) were finally included in the meta-analysis. Colchicine was associated with a decreased risk for myocardial infarction (pooled odds ratio 0.35, 95% confidence interval 0.23-0.55, p < 0.00001).

CONCLUSIONS:

Colchicine was effective in reducing the incidence of MI in patients with gout.

• Authors: Huipeng Wan, Linhong Zeng, Ruihai Xiao, Xiaoyi Tang, Yan Shu, Shaochen Shen
• Journal: Zeitschrift fur Rheumatologie (Z Rheumatol) Vol. 81 Issue 6 Pg. 501-506 (Aug 2022) ISSN: 1435-1250 [Electronic] Germany
• Vernacular Title: Colchicin mit Risikoreduktion für Herzinfarkt bei Gichtpatienten verknüpft: systematische Übersicht und Metaanalyse.
• PMID: 35794279 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Chemical References

• Gout Suppressants
• Colchicine

Topics

• Colchicine (therapeutic use)
• Gout (drug therapy, epidemiology)
• Gout Suppressants (therapeutic use)
• Humans
• Myocardial Infarction (chemically induced, epidemiology, prevention & control)
• Risk Reduction Behavior